On this page
Furosemide
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Increased Diuresis at Loop of Henle [PE] | PE | All 12 members |
| Loop Diuretic [EPC] | EPC | All 12 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 076796-001 | FUROSEMIDE | TABLET | FUROSEMIDE | Prescription | AB | ||
| 076796-002 | FUROSEMIDE | TABLET | FUROSEMIDE | Prescription | AB | ||
| 076796-003 | FUROSEMIDE | TABLET | FUROSEMIDE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 20 | Labeling | Approved | May 31, 2020 | Standard |
| Supplement | 16 | Labeling | Approved | May 31, 2020 | Standard |
| Supplement | 11 | Labeling | Approved | May 9, 2012 | Standard |
| Supplement | 9 | Labeling | Approved | January 27, 2011 | — |
| Supplement | 5 | Labeling | Approved | February 20, 2009 | — |
| Supplement | 4 | Labeling | Approved | August 9, 2007 | — |
| Supplement | 2 | Labeling | Approved | May 1, 2006 | — |
| Original application | 1 | Approved | March 26, 2004 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260429). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide tablets are particularly useful when an agent with greater diuretic potential is desired. Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Edema Furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide tablets are particularly useful when an agent with greater diuretic potential is desired.
Hypertension Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Edema Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Adults - The usual initial dose of furosemide tablets is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (e.g., at 8 am and 2 pm). The dose of furosemide tablets may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states. Edema may be most efficiently and safely mobilized by giving furosemide tablets on 2 to 4 consecutive days each week. When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable (see PRECAUTIONS: Laboratory Tests ). Geriatric Patients - In general, dose selection for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use ). Pediatric Patients - The usual initial dose of oral furosemide in pediatric patients is 2 mg/kg body weight, given as a single dose. If the diuretic response is not satisfactory after the initial dose, dosage may be increased by 1 or 2 mg/kg no sooner than 6 to 8 hours after the previous dose. Doses greater than 6 mg/kg body weight are not recommended. For maintenance therapy in pediatric patients, the dose should be adjusted to the minimum effective level. Hypertension Therapy should be individualized according to the patient's response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response. Adults - The usual initial dose of furosemide tablets for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents. Changes in blood pressure must be carefully monitored when furosemide tablets are used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50 percent when furosemide tablets are added to the regimen. As the blood pressure falls under the potentiating effect of furosemide tablets, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary. Geriatric Patients - In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use ).
Edema Therapy should be individualized according to patient response to gain maximal therapeutic response and to determine the minimal dose needed to maintain that response. Adults - The usual initial dose of furosemide tablets is 20 to 80 mg given as a single dose. Ordinarily a prompt diuresis ensues. If needed, the same dose can be administered 6 to 8 hours later or the dose may be increased. The dose may be raised by 20 or 40 mg and given not sooner than 6 to 8 hours after the previous dose until the desired diuretic effect has been obtained. The individually determined single dose should then be given once or twice daily (e.g., at 8 am and 2 pm). The dose of furosemide tablets may be carefully titrated up to 600 mg/day in patients with clinically severe edematous states. Edema may be most efficiently and safely mobilized by giving furosemide tablets on 2 to 4 consecutive days each week. When doses exceeding 80 mg/day are given for prolonged periods, careful clinical observation and laboratory monitoring are particularly advisable (see PRECAUTIONS: Laboratory Tests ). Geriatric P …
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.
Warnings and Cautions
openFDA Drug LabelingWARNINGS In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4mg furosemide per minute has been used) (see PRECAUTIONS : Drug Interactions).
Warnings
openFDA Drug LabelingWARNINGS SECTION Furosemide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. Therefore, careful medical supervision is required and dose and dose schedule must be adjusted to the individual patient's needs (see DOSAGE AND ADMINISTRATION ).
WARNINGS SECTION In patients with hepatic cirrhosis and ascites, furosemide therapy is best initiated in the hospital. In hepatic coma and in states of electrolyte depletion, therapy should not be instituted until the basic condition is improved. Sudden alterations of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma; therefore, strict observation is necessary during the period of diuresis. Supplemental potassium chloride and, if required, an aldosterone antagonist are helpful in preventing hypokalemia and metabolic alkalosis. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, furosemide should be discontinued. Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs. If the physician elects to use high dose parenteral therapy, controlled intravenous infusion is advisable (for adults, an infusion rate not exceeding 4 mg furosemide per minute has been used) (see PRECAUTIONS: Drug Interactions ).
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Adverse reactions are categorized below by organ system and listed by decreasing severity. Gastrointestinal System Reactions 1. hepatic encephalopathy in patients with hepato-cellular insufficiency 2. pancreatitis 3. jaundice (intrahepatic cholestatic jaundice) 4. increased liver enzymes 5. anorexia 6. oral and gastric irritation 7. cramping 8. diarrhea 9. constipation 10. nausea 11. vomiting Systemic Hypersensitivity Reactions 1. Severe anaphylactic or anaphylactoid reactions (e.g. with shock) 2. systemic vasculitis 3. interstitial nephritis 4. necrotizing angiitis Central Nervous System Reactions 1. tinnitus and hearing loss 2. paresthesias 3. vertigo 4. dizziness 5. headache 6. blurred vision 7. xanthopsia Hematologic Reactions 1. aplastic anemia 2. thrombocytopenia 3. agranulocytosis 4. hemolytic anemia 5. leukopenia 6. anemia 7. eosinophilia Dermatologic-Hypersensitivity Reactions 1. toxic epidermal necrolysis 2. Stevens-Johnson Syndrome 3. erythema multiforme 4. drug rash with eosinophilia and systemic symptoms 5. acute generalized exanthematous pustulosis 6. exfoliative dermatitis 7. bullous pemphigoid 8. purpura 9. photosensitivity 10. rash 11. pruritis 12. urticaria Cardiovascular Reaction 1. Orthostatic hypotension may occur and be aggravated by alcohol, barbiturates or narcotics. 2. Increase in cholesterol and triglyceride serum levels Other Reactions 1. hyperglycemia 2. glycosuria 3. hyperuricemia 4. muscle spasm 5. weakness 6. restlessness 7. urinary bladder spasm 8. thrombophlebitis 9. fever Whenever adverse reactions are moderate or severe, Furosemide tablets dosage should be reduced or therapy withdrawn. CALL YOUR DOCTOR FOR MEDICAL ADVICE ABOUT SIDE EFFECTS. YOU MAY REPORT SIDE EFFECTS TO THE FDA AT 1-800-FDA-1088 OR LEADING PHARMA, LLC AT 1-844-740-7500.
Drug Interactions
openFDA Drug LabelingDrug Interactions Furosemide tablets may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination. Furosemide tablets should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with Furosemide tablets, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites. There is a risk of ototoxic effects if cisplatin and Furosemide tablets are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if Furosemide tablets are not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. Furosemide tablets have a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Lithium generally should not be given with diuretics because they reduce lithium’s renal clearance and add a high risk of lithium toxicity. Furosemide tablets combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure. An interruption or reduction in the dosage of Furosemide tablets, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary. Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs. Furosemide tablets may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively. Simultaneous administration of sucralfate and Furosemide tablets may reduce the natriuretic and antihypertensive effects of Furosemide tablets. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of Furosemide tablets is achieved. The intake of Furosemide tablets and sucralfate should be separated by at least two hours. In isolated cases, intravenous administration of Furosemide tablets within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Use of Furosemide tablets concomitantly with chloral hydrate is, therefore, not recommended. Phenytoin interferes directly with renal action of Furosemide tablets. There is evidence that treatment with phenytoin leads to decrease intestinal absorption of Furosemide tablets, and consequently to lower peak serum furosemide concentrations. Methotrexate and other drugs that, like Furosemide tablets, undergo significant renal tubular secretion may reduce the effect of Furosemide tablets. Conversely, Furosemide tablets may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of both Furosemide tablets and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of Furosemide tablets. Furosemide tablets can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment. Concomitant use of cyclosporine and Furosemide tablets is associated with increased risk of gouty arthritis secondary to Furosemide tablets-induced hyperurecemia and cyclosporine impairment of renal urate excretion. High doses (>80mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum pota …
Description
openFDA Drug LabelingDESCRIPTION Each tablet for oral administration contains: Furosemide, USP . . . . . . . . . . . . . . . . 20 mg, 40 mg and 80 mg Each mL of Oral Solution for oral administration contains: Furosemide, USP . . . . . . . . . . . . . . . . 10 mg per mL or 8 mg (40 mg per 5 mL) Furosemide is a diuretic which is an anthranilic acid derivative. Chemically, it is 4-chloro- N -furfuryl-5-sulfamoylanthranilic acid. Furosemide is a white to slightly yellow, crystalline powder. It is practically insoluble in water; freely soluble in acetone, dimethylformamide and in solutions of alkali hydroxides; soluble in methanol; sparingly soluble in alcohol; slightly soluble in ether; very slightly soluble in chloroform. The CAS Registry Number is 54-31-9. The structural formula is as follows: C 12 H 11 ClN 2 O 5 S M.W. 330.74 Furosemide Tablets, USP are available for oral administration containing 20 mg, 40 mg or 80 mg of Furosemide, USP. The tablets meet Dissolution Test 1. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, microcrystalline cellulose, pregelatinized starch, purified water, sodium lauryl sulfate, sodium starch glycolate and stearic acid. Furosemide Oral Solution, USP is also available for oral administration containing either 10 mg per mL or 40 mg per 5 mL. The oral solution contains the following inactive ingredients: D and C Yellow No. 10, FD and C Yellow No. 6, flavors, potassium carbonate 11⁄2 hydrate, propylene glycol, purified water and sorbitol solution. The 10 mg/mL solution is orange flavored and contains prosweet liquid and saccharin sodium. The 40 mg/5 mL solution is pineapple-peach flavored and contains sweet tone. furosemide structural formula image
Overdosage
openFDA Drug LabelingOVERDOSAGE The principal signs and symptoms of overdose with FUROSEMIDE TABLET are dehydration, blood volume reduction, hypotension, electrolyte imbalance, hypokalemia and hypochloremic alkalosis, and are extensions of its diuretic action. The acute toxicity of FUROSEMIDE TABLET has been determined in mice, rats and dogs. In all three, the oral LD 50 exceeded 1000 mg/kg body weight, while the intravenous LD 50 ranged from 300 to 680 mg/kg. The acute intragastric toxicity in neonatal rats is 7 to 10 times that of adult rats. The concentration of FUROSEMIDE TABLET in biological fluids associated with toxicity or death is not known. Treatment of overdosage is supportive and consists of replacement of excessive fluid and electrolyte losses. Serum electrolytes, carbon dioxide level and blood pressure should be determined frequently. Adequate drainage must be assured in patients with urinary bladder outlet obstruction (such as prostatic hypertrophy). Hemodialysis does not accelerate furosemide elimination.
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Furosemide Tablets USP 20 mg tablets are supplied as white, flat tablets with beveled edges, product identification “54 840” debossed on one side. NDC 0054-8297-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4297-25: Bottle of 100 Tablets NDC 0054-4297-31: Bottle of 1000 Tablets 40 mg tablets are supplied as white, flat tablets with beveled edges, scored on one side and product identification “54 583” debossed on one side. NDC 0054-8299-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4299-25: Bottle of 100 Tablets NDC 0054-4299-31: Bottle of 1000 Tablets 80 mg tablets are supplied as white, flat tablets with beveled edges, scored on one side and product identification “54 533” debossed on one side. NDC 0054-8301-25: Unit dose amber blisters, 10 Tablets per strip, 10 strips per shelf pack, 10 shelf packs per shipper NDC 0054-4301-25: Bottle of 100 Tablets NDC 0054-4301-29: Bottle of 500 Tablets Store and Dispense Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Note: Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF. Exposure to light may cause slight discoloration. Discolored tablets should not be dispensed. Protect From Moisture. PROTECT FROM LIGHT. Furosemide Oral Solution USP 10 mg per mL oral solution is supplied as a (orange-flavored) clear, orange-colored solution. NDC 0054-3294-46: Bottle of 60 mL Dispense only in this bottle and only with the calibrated dropper provided. NDC 0054-3294-50: Bottle of 120 mL Dispense only in this bottle. PROTECT FROM LIGHT. NOTE: DISCARD OPENED BOTTLE AFTER 90 DAYS. 40 mg per 5 mL oral solution is supplied as a (pineapple-peach flavored) clear, orange-colored solution. NDC 0054-3298-63: Bottle of 500 mL Dispense in a tight, light-resistant, child-resistant container as defined in the USP/NF. PROTECT FROM LIGHT. Store and Dispense Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 4052002//11 Revised January 2016
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: FUROSEMIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | April 29, 2026 | Leading Pharma, LLC | CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit. | Ongoing |
| Class II | January 28, 2026 | Graviti Pharmaceuticals Private Limited | Presence of Foreign Substance | Ongoing |
| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-2713-0 | 50090-2713 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-2713-0) | December 14, 2016 |
| 50090-3313-0 | 50090-3313 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-3313-0) | September 23, 2021 |
| 50090-3313-1 | 50090-3313 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-3313-1) | January 2, 2018 |
| 50090-3313-3 | 50090-3313 | A-S Medication Solutions | 60 TABLET in 1 BOTTLE (50090-3313-3) | January 12, 2022 |
| 50090-3313-9 | 50090-3313 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-3313-9) | December 27, 2017 |
| 50090-5429-0 | 50090-5429 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-5429-0) | January 11, 2021 |
| 50090-5429-1 | 50090-5429 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-5429-1) | January 11, 2021 |
| 50090-5429-7 | 50090-5429 | A-S Medication Solutions | 200 TABLET in 1 BOTTLE (50090-5429-7) | January 17, 2023 |
| 50090-5429-8 | 50090-5429 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-5429-8) | January 11, 2021 |
| 50090-5702-0 | 50090-5702 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-5702-0) | September 23, 2021 |
| 50090-5702-1 | 50090-5702 | A-S Medication Solutions | 180 TABLET in 1 BOTTLE (50090-5702-1) | April 18, 2023 |
| 50090-6219-0 | 50090-6219 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-6219-0) | November 10, 2022 |
| 50090-6219-1 | 50090-6219 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-6219-1) | November 10, 2022 |
| 50090-6219-7 | 50090-6219 | A-S Medication Solutions | 200 TABLET in 1 BOTTLE (50090-6219-7) | November 10, 2022 |
| 50090-6219-8 | 50090-6219 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-6219-8) | November 10, 2022 |
| 50090-6642-0 | 50090-6642 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-6642-0) | August 29, 2023 |
| 50090-6642-1 | 50090-6642 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-6642-1) | August 29, 2023 |
| 50090-6642-8 | 50090-6642 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-6642-8) | August 29, 2023 |
| 50090-6646-0 | 50090-6646 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-6646-0) | August 29, 2023 |
| 50090-6646-1 | 50090-6646 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-6646-1) | August 29, 2023 |
| 50090-6646-3 | 50090-6646 | A-S Medication Solutions | 60 TABLET in 1 BOTTLE (50090-6646-3) | August 29, 2023 |
| 50090-6646-9 | 50090-6646 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-6646-9) | August 29, 2023 |
| 50090-6647-1 | 50090-6647 | A-S Medication Solutions | 180 TABLET in 1 BOTTLE (50090-6647-1) | August 29, 2023 |
| 50090-6937-0 | 50090-6937 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-6937-0) | December 15, 2023 |
| 50090-6942-0 | 50090-6942 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-6942-0) | December 15, 2023 |
| 50090-7703-0 | 50090-7703 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-7703-0) | October 14, 2025 |
| 50090-7703-1 | 50090-7703 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-7703-1) | October 14, 2025 |
| 50090-7703-3 | 50090-7703 | A-S Medication Solutions | 60 TABLET in 1 BOTTLE (50090-7703-3) | October 14, 2025 |
| 50090-7703-9 | 50090-7703 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-7703-9) | October 14, 2025 |
| 50090-7704-1 | 50090-7704 | A-S Medication Solutions | 180 TABLET in 1 BOTTLE (50090-7704-1) | October 14, 2025 |
| 50090-7705-0 | 50090-7705 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-7705-0) | October 14, 2025 |
| 50090-7706-0 | 50090-7706 | A-S Medication Solutions | 30 TABLET in 1 BOTTLE (50090-7706-0) | October 14, 2025 |
| 50090-7706-1 | 50090-7706 | A-S Medication Solutions | 100 TABLET in 1 BOTTLE (50090-7706-1) | October 14, 2025 |
| 50090-7706-7 | 50090-7706 | A-S Medication Solutions | 200 TABLET in 1 BOTTLE (50090-7706-7) | October 14, 2025 |
| 50090-7706-8 | 50090-7706 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-7706-8) | October 14, 2025 |
| 50090-7708-0 | 50090-7708 | A-S Medication Solutions | 90 TABLET in 1 BOTTLE (50090-7708-0) | October 14, 2025 |
| 43353-069-30 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (43353-069-30) | June 19, 2017 |
| 43353-069-45 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE (43353-069-45) | June 19, 2017 |
| 43353-069-53 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (43353-069-53) | June 19, 2017 |
| 43353-069-60 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (43353-069-60) | June 19, 2017 |
| 43353-069-80 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (43353-069-80) | June 19, 2017 |
| 43353-747-30 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (43353-747-30) | May 1, 2017 |
| 43353-747-45 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE, PLASTIC (43353-747-45) | August 22, 2017 |
| 43353-747-53 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE, PLASTIC (43353-747-53) | May 1, 2017 |
| 43353-747-60 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (43353-747-60) | August 2, 2011 |
| 43353-747-80 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE, PLASTIC (43353-747-80) | May 1, 2017 |
| 43353-747-92 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | 270 TABLET in 1 BOTTLE, PLASTIC (43353-747-92) | August 22, 2017 |
| 71610-049-30 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (71610-049-30) | April 16, 2018 |
| 71610-049-45 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE, PLASTIC (71610-049-45) | April 16, 2018 |
| 71610-049-53 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE, PLASTIC (71610-049-53) | April 16, 2018 |
| 71610-049-60 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (71610-049-60) | April 16, 2018 |
| 71610-049-80 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE, PLASTIC (71610-049-80) | April 16, 2018 |
| 71610-096-30 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (71610-096-30) | July 13, 2018 |
| 71610-096-45 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE, PLASTIC (71610-096-45) | May 31, 2024 |
| 71610-096-53 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE, PLASTIC (71610-096-53) | July 13, 2018 |
| 71610-096-60 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (71610-096-60) | July 13, 2018 |
| 71610-096-80 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE, PLASTIC (71610-096-80) | July 13, 2018 |
| 71610-634-30 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (71610-634-30) | February 22, 2022 |
| 71610-634-45 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE (71610-634-45) | February 22, 2022 |
| 71610-634-53 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (71610-634-53) | February 22, 2022 |
| 71610-634-60 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (71610-634-60) | February 22, 2022 |
| 71610-634-80 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (71610-634-80) | February 22, 2022 |
| 71610-635-30 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (71610-635-30) | February 22, 2022 |
| 71610-635-45 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE (71610-635-45) | March 8, 2022 |
| 71610-635-53 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (71610-635-53) | February 22, 2022 |
| 71610-635-60 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (71610-635-60) | February 22, 2022 |
| 71610-635-80 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (71610-635-80) | February 22, 2022 |
| 71610-635-92 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | 270 TABLET in 1 BOTTLE (71610-635-92) | February 22, 2022 |
| 71610-636-30 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (71610-636-30) | February 24, 2022 |
| 71610-636-45 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE (71610-636-45) | February 24, 2022 |
| 71610-636-53 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (71610-636-53) | February 24, 2022 |
| 71610-636-60 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (71610-636-60) | February 24, 2022 |
| 71610-636-80 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (71610-636-80) | February 24, 2022 |
| 71610-843-30 | 71610-843 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (71610-843-30) | June 26, 2024 |
| 71610-843-53 | 71610-843 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (71610-843-53) | June 26, 2024 |
| 71610-843-60 | 71610-843 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (71610-843-60) | June 26, 2024 |
| 71610-843-80 | 71610-843 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (71610-843-80) | June 26, 2024 |
| 71610-951-30 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | 30 TABLET in 1 BOTTLE (71610-951-30) | October 13, 2025 |
| 71610-951-45 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | 45 TABLET in 1 BOTTLE (71610-951-45) | September 19, 2025 |
| 71610-951-53 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | 60 TABLET in 1 BOTTLE (71610-951-53) | September 19, 2025 |
| 71610-951-60 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | 90 TABLET in 1 BOTTLE (71610-951-60) | September 19, 2025 |
| 71610-951-80 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | 180 TABLET in 1 BOTTLE (71610-951-80) | September 19, 2025 |
| 59651-796-01 | 59651-796 | Aurobindo Pharma Limited | 100 TABLET in 1 BOTTLE (59651-796-01) | July 17, 2025 |
| 59651-796-91 | 59651-796 | Aurobindo Pharma Limited | 100000 TABLET in 1 BAG (59651-796-91) | July 17, 2025 |
| 59651-796-99 | 59651-796 | Aurobindo Pharma Limited | 1000 TABLET in 1 BOTTLE (59651-796-99) | July 17, 2025 |
| 59651-797-01 | 59651-797 | Aurobindo Pharma Limited | 100 TABLET in 1 BOTTLE (59651-797-01) | July 17, 2025 |
| 59651-797-72 | 59651-797 | Aurobindo Pharma Limited | 75000 TABLET in 1 BAG (59651-797-72) | July 17, 2025 |
| 59651-797-99 | 59651-797 | Aurobindo Pharma Limited | 1000 TABLET in 1 BOTTLE (59651-797-99) | July 17, 2025 |
| 59651-798-01 | 59651-798 | Aurobindo Pharma Limited | 100 TABLET in 1 BOTTLE (59651-798-01) | July 17, 2025 |
| 59651-798-05 | 59651-798 | Aurobindo Pharma Limited | 500 TABLET in 1 BOTTLE (59651-798-05) | July 17, 2025 |
| 59651-798-62 | 59651-798 | Aurobindo Pharma Limited | 30000 TABLET in 1 BAG (59651-798-62) | July 17, 2025 |
| 42291-468-01 | 42291-468 | AvKARE | 100 TABLET in 1 BOTTLE (42291-468-01) | January 4, 2022 |
| 42291-468-10 | 42291-468 | AvKARE | 1000 TABLET in 1 BOTTLE (42291-468-10) | January 4, 2022 |
| 42291-468-90 | 42291-468 | AvKARE | 90 TABLET in 1 BOTTLE (42291-468-90) | January 4, 2022 |
| 42291-469-01 | 42291-469 | AvKARE | 100 TABLET in 1 BOTTLE (42291-469-01) | January 4, 2022 |
| 42291-469-10 | 42291-469 | AvKARE | 1000 TABLET in 1 BOTTLE (42291-469-10) | January 4, 2022 |
| 42291-469-90 | 42291-469 | AvKARE | 90 TABLET in 1 BOTTLE (42291-469-90) | January 4, 2022 |
| 42291-470-01 | 42291-470 | AvKARE | 100 TABLET in 1 BOTTLE (42291-470-01) | January 4, 2022 |
| 42291-470-50 | 42291-470 | AvKARE | 500 TABLET in 1 BOTTLE (42291-470-50) | January 4, 2022 |
| 63629-1119-1 | 63629-1119 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (63629-1119-1) | July 30, 2020 |
| 63629-1120-1 | 63629-1120 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (63629-1120-1) | July 30, 2020 |
| 63629-1214-1 | 63629-1214 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE (63629-1214-1) | January 14, 2021 |
| 63629-1215-1 | 63629-1215 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1215-1) | January 14, 2021 |
| 63629-1216-1 | 63629-1216 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (63629-1216-1) | January 14, 2021 |
| 63629-1217-1 | 63629-1217 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE (63629-1217-1) | January 14, 2021 |
| 71335-0384-1 | 71335-0384 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0384-1) | February 9, 2022 |
| 71335-0384-2 | 71335-0384 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0384-2) | February 9, 2022 |
| 71335-0384-3 | 71335-0384 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0384-3) | February 9, 2022 |
| 71335-0384-4 | 71335-0384 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-0384-4) | February 9, 2022 |
| 71335-0384-5 | 71335-0384 | Bryant Ranch Prepack | 7 TABLET in 1 BOTTLE (71335-0384-5) | February 9, 2022 |
| 71335-0384-6 | 71335-0384 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0384-6) | February 9, 2022 |
| 71335-0384-7 | 71335-0384 | Bryant Ranch Prepack | 14 TABLET in 1 BOTTLE (71335-0384-7) | February 9, 2022 |
| 71335-0384-8 | 71335-0384 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-0384-8) | February 9, 2022 |
| 71335-0384-9 | 71335-0384 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-0384-9) | February 9, 2022 |
| 71335-0842-1 | 71335-0842 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-0842-1) | May 31, 2018 |
| 71335-0842-2 | 71335-0842 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0842-2) | May 31, 2018 |
| 71335-0842-3 | 71335-0842 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-0842-3) | May 31, 2018 |
| 71335-0842-4 | 71335-0842 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0842-4) | May 31, 2018 |
| 71335-0842-5 | 71335-0842 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0842-5) | May 31, 2018 |
| 71335-0842-6 | 71335-0842 | Bryant Ranch Prepack | 7 TABLET in 1 BOTTLE (71335-0842-6) | May 31, 2018 |
| 71335-0842-7 | 71335-0842 | Bryant Ranch Prepack | 14 TABLET in 1 BOTTLE (71335-0842-7) | May 31, 2018 |
| 71335-0842-8 | 71335-0842 | Bryant Ranch Prepack | 180 TABLET in 1 BOTTLE (71335-0842-8) | May 31, 2018 |
| 71335-0842-9 | 71335-0842 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-0842-9) | May 31, 2018 |
| 71335-0852-1 | 71335-0852 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-0852-1) | June 22, 2018 |
| 71335-0852-2 | 71335-0852 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-0852-2) | June 22, 2018 |
| 71335-0852-3 | 71335-0852 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-0852-3) | June 22, 2018 |
| 71335-0852-4 | 71335-0852 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-0852-4) | June 22, 2018 |
| 71335-0852-5 | 71335-0852 | Bryant Ranch Prepack | 7 TABLET in 1 BOTTLE (71335-0852-5) | June 22, 2018 |
| 71335-0852-6 | 71335-0852 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-0852-6) | June 22, 2018 |
| 71335-0852-7 | 71335-0852 | Bryant Ranch Prepack | 14 TABLET in 1 BOTTLE (71335-0852-7) | June 22, 2018 |
| 71335-0852-8 | 71335-0852 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-0852-8) | June 22, 2018 |
| 71335-0852-9 | 71335-0852 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-0852-9) | June 22, 2018 |
| 71335-2317-1 | 71335-2317 | Bryant Ranch Prepack | 40 TABLET in 1 BOTTLE (71335-2317-1) | January 2, 2024 |
| 71335-2317-2 | 71335-2317 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2317-2) | January 2, 2024 |
| 71335-2317-3 | 71335-2317 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2317-3) | January 2, 2024 |
| 71335-2317-4 | 71335-2317 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2317-4) | January 2, 2024 |
| 71335-2317-5 | 71335-2317 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2317-5) | January 2, 2024 |
| 71335-2317-6 | 71335-2317 | Bryant Ranch Prepack | 7 TABLET in 1 BOTTLE (71335-2317-6) | January 2, 2024 |
| 71335-2317-7 | 71335-2317 | Bryant Ranch Prepack | 14 TABLET in 1 BOTTLE (71335-2317-7) | January 2, 2024 |
| 71335-2317-8 | 71335-2317 | Bryant Ranch Prepack | 180 TABLET in 1 BOTTLE (71335-2317-8) | January 2, 2024 |
| 71335-2317-9 | 71335-2317 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2317-9) | January 2, 2024 |
| 71335-2319-0 | 71335-2319 | Bryant Ranch Prepack | 6 TABLET in 1 BOTTLE (71335-2319-0) | January 4, 2024 |
| 71335-2319-1 | 71335-2319 | Bryant Ranch Prepack | 30 TABLET in 1 BOTTLE (71335-2319-1) | January 4, 2024 |
| 71335-2319-2 | 71335-2319 | Bryant Ranch Prepack | 90 TABLET in 1 BOTTLE (71335-2319-2) | January 4, 2024 |
| 71335-2319-3 | 71335-2319 | Bryant Ranch Prepack | 60 TABLET in 1 BOTTLE (71335-2319-3) | January 4, 2024 |
| 71335-2319-4 | 71335-2319 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE (71335-2319-4) | January 4, 2024 |
| 71335-2319-5 | 71335-2319 | Bryant Ranch Prepack | 7 TABLET in 1 BOTTLE (71335-2319-5) | January 4, 2024 |
| 71335-2319-6 | 71335-2319 | Bryant Ranch Prepack | 28 TABLET in 1 BOTTLE (71335-2319-6) | January 4, 2024 |
| 71335-2319-7 | 71335-2319 | Bryant Ranch Prepack | 14 TABLET in 1 BOTTLE (71335-2319-7) | January 4, 2024 |
| 71335-2319-8 | 71335-2319 | Bryant Ranch Prepack | 10 TABLET in 1 BOTTLE (71335-2319-8) | January 4, 2024 |
| 71335-2319-9 | 71335-2319 | Bryant Ranch Prepack | 20 TABLET in 1 BOTTLE (71335-2319-9) | January 4, 2024 |
| 72162-1360-0 | 72162-1360 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (72162-1360-0) | February 2, 2024 |
| 72162-1360-1 | 72162-1360 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1360-1) | February 2, 2024 |
| 72162-1361-0 | 72162-1361 | Bryant Ranch Prepack | 1000 TABLET in 1 BOTTLE, PLASTIC (72162-1361-0) | October 4, 2023 |
| 72162-1361-1 | 72162-1361 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1361-1) | October 4, 2023 |
| 72162-1362-1 | 72162-1362 | Bryant Ranch Prepack | 100 TABLET in 1 BOTTLE, PLASTIC (72162-1362-1) | February 2, 2024 |
| 72162-1362-5 | 72162-1362 | Bryant Ranch Prepack | 500 TABLET in 1 BOTTLE, PLASTIC (72162-1362-5) | February 2, 2024 |
| 17224-178-21 | 17224-178 | Calvin Scott & Co., Inc. | 21 TABLET in 1 BOTTLE (17224-178-21) | May 15, 2016 |
| 17224-178-30 | 17224-178 | Calvin Scott & Co., Inc. | 30 TABLET in 1 BOTTLE (17224-178-30) | May 15, 2016 |
| 17224-185-21 | 17224-185 | Calvin Scott & Co., Inc. | 21 TABLET in 1 BOTTLE, PLASTIC (17224-185-21) | May 15, 2016 |
| 55154-2348-0 | 55154-2348 | Cardinal Health 107, LLC | 10 BLISTER PACK in 1 BAG (55154-2348-0) / 1 TABLET in 1 BLISTER PACK | December 4, 2024 |
| 55154-2349-0 | 55154-2349 | Cardinal Health 107, LLC | 10 BLISTER PACK in 1 BAG (55154-2349-0) / 1 TABLET in 1 BLISTER PACK | December 4, 2024 |
| 62135-753-90 | 62135-753 | Chartwell RX, LLC | 90 TABLET in 1 PACKAGE (62135-753-90) | April 17, 2024 |
| 62135-754-90 | 62135-754 | Chartwell RX, LLC | 90 TABLET in 1 PACKAGE (62135-754-90) | April 17, 2024 |
| 67046-0768-3 | 67046-0768 | Coupler LLC | 30 TABLET in 1 BLISTER PACK (67046-0768-3) | June 10, 2026 |
| 67046-1555-3 | 67046-1555 | Coupler LLC | 30 TABLET in 1 BLISTER PACK (67046-1555-3) | April 29, 2025 |
| 67046-1589-3 | 67046-1589 | Coupler LLC | 30 TABLET in 1 BLISTER PACK (67046-1589-3) | September 16, 2025 |
| 67046-1663-3 | 67046-1663 | Coupler LLC | 30 TABLET in 1 BLISTER PACK (67046-1663-3) | March 11, 2026 |
| 61919-242-30 | 61919-242 | DIRECT RX | 30 TABLET in 1 BOTTLE (61919-242-30) | June 18, 2020 |
| 61919-242-90 | 61919-242 | DIRECT RX | 90 TABLET in 1 BOTTLE (61919-242-90) | June 18, 2020 |
| 61919-255-30 | 61919-255 | Direct_Rx | 30 TABLET in 1 BOTTLE (61919-255-30) | October 21, 2021 |
| 61919-255-90 | 61919-255 | Direct_Rx | 90 TABLET in 1 BOTTLE (61919-255-90) | October 21, 2021 |
| 63561-0164-1 | 63561-0164 | Granulation Technology, Inc. | 100 TABLET in 1 BOTTLE (63561-0164-1) | January 15, 2026 |
| 63561-0164-2 | 63561-0164 | Granulation Technology, Inc. | 1000 TABLET in 1 BOTTLE (63561-0164-2) | December 18, 2025 |
| 63561-0164-9 | 63561-0164 | Granulation Technology, Inc. | 90 TABLET in 1 BOTTLE (63561-0164-9) | December 18, 2025 |
| 63561-0165-1 | 63561-0165 | Granulation Technology, Inc. | 100 TABLET in 1 BOTTLE (63561-0165-1) | January 15, 2026 |
| 63561-0165-2 | 63561-0165 | Granulation Technology, Inc. | 1000 TABLET in 1 BOTTLE (63561-0165-2) | December 18, 2025 |
| 63561-0165-9 | 63561-0165 | Granulation Technology, Inc. | 90 TABLET in 1 BOTTLE (63561-0165-9) | December 18, 2025 |
| 63561-0166-1 | 63561-0166 | Granulation Technology, Inc. | 100 TABLET in 1 BOTTLE (63561-0166-1) | January 15, 2026 |
| 63561-0166-5 | 63561-0166 | Granulation Technology, Inc. | 500 TABLET in 1 BOTTLE (63561-0166-5) | December 18, 2025 |
| 63561-0166-9 | 63561-0166 | Granulation Technology, Inc. | 90 TABLET in 1 BOTTLE (63561-0166-9) | December 18, 2025 |
| 0054-4297-25 | 0054-4297 | Hikma Pharmaceuticals USA Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (0054-4297-25) | November 10, 1983 |
| 0054-4297-31 | 0054-4297 | Hikma Pharmaceuticals USA Inc. | 1000 TABLET in 1 BOTTLE, PLASTIC (0054-4297-31) | November 10, 1983 |
| 0054-4299-25 | 0054-4299 | Hikma Pharmaceuticals USA Inc. | 100 TABLET in 1 BOTTLE (0054-4299-25) | November 10, 1983 |
| 0054-4299-31 | 0054-4299 | Hikma Pharmaceuticals USA Inc. | 1000 TABLET in 1 BOTTLE (0054-4299-31) | November 10, 1983 |
| 0054-4301-25 | 0054-4301 | Hikma Pharmaceuticals USA Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (0054-4301-25) | March 13, 1991 |
| 0054-4301-29 | 0054-4301 | Hikma Pharmaceuticals USA Inc. | 500 TABLET in 1 BOTTLE, PLASTIC (0054-4301-29) | March 13, 1991 |
| 0054-8297-25 | 0054-8297 | Hikma Pharmaceuticals USA Inc. | 10 BLISTER PACK in 1 CARTON (0054-8297-25) / 10 TABLET in 1 BLISTER PACK | November 10, 1983 |
| 0054-8299-25 | 0054-8299 | Hikma Pharmaceuticals USA Inc. | 10 BLISTER PACK in 1 CARTON (0054-8299-25) / 10 TABLET in 1 BLISTER PACK | November 10, 1983 |
| 0054-8301-25 | 0054-8301 | Hikma Pharmaceuticals USA Inc. | 10 BLISTER PACK in 1 CARTON (0054-8301-25) / 10 TABLET in 1 BLISTER PACK | March 13, 1991 |
| 83980-002-01 | 83980-002 | Ipca Laboratories Limited | 100 TABLET in 1 BOTTLE (83980-002-01) | June 3, 2024 |
| 83980-002-10 | 83980-002 | Ipca Laboratories Limited | 1000 TABLET in 1 BOTTLE (83980-002-10) | June 3, 2024 |
| 83980-002-97 | 83980-002 | Ipca Laboratories Limited | 10 TABLET in 1 BOTTLE (83980-002-97) | June 3, 2024 |
| 83980-003-01 | 83980-003 | Ipca Laboratories Limited | 100 TABLET in 1 BOTTLE (83980-003-01) | June 3, 2024 |
| 83980-003-10 | 83980-003 | Ipca Laboratories Limited | 1000 TABLET in 1 BOTTLE (83980-003-10) | June 3, 2024 |
| 83980-003-97 | 83980-003 | Ipca Laboratories Limited | 10 TABLET in 1 BOTTLE (83980-003-97) | June 3, 2024 |
| 83980-004-01 | 83980-004 | Ipca Laboratories Limited | 100 TABLET in 1 BOTTLE (83980-004-01) | June 3, 2024 |
| 83980-004-05 | 83980-004 | Ipca Laboratories Limited | 500 TABLET in 1 BOTTLE (83980-004-05) | June 3, 2024 |
| 83980-004-10 | 83980-004 | Ipca Laboratories Limited | 1000 TABLET in 1 BOTTLE (83980-004-10) | June 3, 2024 |
| 83980-004-97 | 83980-004 | Ipca Laboratories Limited | 10 TABLET in 1 BOTTLE (83980-004-97) | June 3, 2024 |
| 69315-116-01 | 69315-116 | Leading Pharma, LLC | 100 TABLET in 1 BOTTLE (69315-116-01) | May 15, 2016 |
| 69315-116-10 | 69315-116 | Leading Pharma, LLC | 1000 TABLET in 1 BOTTLE (69315-116-10) | May 15, 2016 |
| 69315-117-01 | 69315-117 | Leading Pharma, LLC | 100 TABLET in 1 BOTTLE (69315-117-01) | May 15, 2016 |
| 69315-117-10 | 69315-117 | Leading Pharma, LLC | 1000 TABLET in 1 BOTTLE (69315-117-10) | May 15, 2016 |
| 69315-118-01 | 69315-118 | Leading Pharma, LLC | 100 TABLET in 1 BOTTLE (69315-118-01) | May 15, 2016 |
| 69315-118-05 | 69315-118 | Leading Pharma, LLC | 500 TABLET in 1 BOTTLE (69315-118-05) | May 15, 2016 |
| 0904-7177-61 | 0904-7177 | Major Pharmaceuticals | 100 BLISTER PACK in 1 CARTON (0904-7177-61) / 1 TABLET in 1 BLISTER PACK | March 26, 2004 |
| 0904-7178-61 | 0904-7178 | Major Pharmaceuticals | 100 BLISTER PACK in 1 CARTON (0904-7178-61) / 1 TABLET in 1 BLISTER PACK | March 26, 2004 |
| 10135-832-01 | 10135-832 | Marlex Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (10135-832-01) | March 1, 2026 |
| 10135-832-10 | 10135-832 | Marlex Pharmaceuticals, Inc. | 1000 TABLET in 1 BOTTLE (10135-832-10) | March 1, 2026 |
| 10135-832-90 | 10135-832 | Marlex Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE (10135-832-90) | March 1, 2026 |
| 10135-833-01 | 10135-833 | Marlex Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (10135-833-01) | March 1, 2026 |
| 10135-833-10 | 10135-833 | Marlex Pharmaceuticals, Inc. | 1000 TABLET in 1 BOTTLE (10135-833-10) | March 1, 2026 |
| 10135-833-90 | 10135-833 | Marlex Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE (10135-833-90) | March 1, 2026 |
| 10135-834-01 | 10135-834 | Marlex Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (10135-834-01) | March 1, 2026 |
| 10135-834-05 | 10135-834 | Marlex Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE (10135-834-05) | March 1, 2026 |
| 10135-834-90 | 10135-834 | Marlex Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE (10135-834-90) | March 1, 2026 |
| 0615-8368-05 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 15 TABLET in 1 BLISTER PACK (0615-8368-05) | December 8, 2020 |
| 0615-8368-07 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 7 TABLET in 1 BLISTER PACK (0615-8368-07) | June 21, 2022 |
| 0615-8368-10 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 10 TABLET in 1 BLISTER PACK (0615-8368-10) | November 18, 2022 |
| 0615-8368-14 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 14 TABLET in 1 BLISTER PACK (0615-8368-14) | June 21, 2022 |
| 0615-8368-28 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 28 TABLET in 1 BLISTER PACK (0615-8368-28) | April 15, 2024 |
| 0615-8368-30 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (0615-8368-30) / 5 TABLET in 1 BLISTER PACK | December 14, 2020 |
| 0615-8368-39 | 0615-8368 | NCS HealthCare of KY, LLC dba Vangard Labs | 30 TABLET in 1 BLISTER PACK (0615-8368-39) | December 8, 2020 |
| 0615-8369-05 | 0615-8369 | NCS HealthCare of KY, LLC dba Vangard Labs | 15 TABLET in 1 BLISTER PACK (0615-8369-05) | December 4, 2020 |
| 0615-8369-07 | 0615-8369 | NCS HealthCare of KY, LLC dba Vangard Labs | 7 TABLET in 1 BLISTER PACK (0615-8369-07) | June 2, 2022 |
| 0615-8369-14 | 0615-8369 | NCS HealthCare of KY, LLC dba Vangard Labs | 14 TABLET in 1 BLISTER PACK (0615-8369-14) | June 2, 2022 |
| 0615-8369-30 | 0615-8369 | NCS HealthCare of KY, LLC dba Vangard Labs | 6 BLISTER PACK in 1 BOX, UNIT-DOSE (0615-8369-30) / 5 TABLET in 1 BLISTER PACK | December 16, 2020 |
| 0615-8369-39 | 0615-8369 | NCS HealthCare of KY, LLC dba Vangard Labs | 30 TABLET in 1 BLISTER PACK (0615-8369-39) | December 4, 2020 |
| 0615-8370-39 | 0615-8370 | NCS HealthCare of KY, LLC dba Vangard Labs | 30 TABLET in 1 BLISTER PACK (0615-8370-39) | December 15, 2020 |
| 51655-269-25 | 51655-269 | Northwind Health Company, LLC | 60 TABLET in 1 BOTTLE, PLASTIC (51655-269-25) | February 9, 2023 |
| 51655-269-26 | 51655-269 | Northwind Health Company, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (51655-269-26) | September 6, 2022 |
| 51655-269-52 | 51655-269 | Northwind Health Company, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (51655-269-52) | August 8, 2022 |
| 51655-269-53 | 51655-269 | Northwind Health Company, LLC | 10 TABLET in 1 BOTTLE, PLASTIC (51655-269-53) | February 9, 2023 |
| 51655-310-53 | 51655-310 | Northwind Health Company, LLC | 10 TABLET in 1 BOTTLE, PLASTIC (51655-310-53) | November 28, 2022 |
| 51655-481-52 | 51655-481 | Northwind Health Company, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (51655-481-52) | November 19, 2020 |
| 51655-481-53 | 51655-481 | Northwind Health Company, LLC | 10 TABLET in 1 BOTTLE, PLASTIC (51655-481-53) | November 30, 2020 |
| 51655-517-26 | 51655-517 | Northwind Health Company, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (51655-517-26) | July 11, 2022 |
| 51655-517-52 | 51655-517 | Northwind Health Company, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (51655-517-52) | June 24, 2022 |
| 82868-050-30 | 82868-050 | Northwind Health Company, LLC | 30 TABLET in 1 BOTTLE, PLASTIC (82868-050-30) | February 29, 2024 |
| 82868-050-90 | 82868-050 | Northwind Health Company, LLC | 90 TABLET in 1 BOTTLE, PLASTIC (82868-050-90) | February 29, 2024 |
| 68071-3673-3 | 68071-3673 | NuCare Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE (68071-3673-3) | August 30, 2024 |
| 68071-3673-9 | 68071-3673 | NuCare Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE (68071-3673-9) | October 16, 2025 |
| 68071-1708-1 | 68071-1708 | NuCare Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE (68071-1708-1) | February 6, 2019 |
| 68071-1809-1 | 68071-1809 | NuCare Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE (68071-1809-1) | January 29, 2019 |
| 68071-2360-1 | 68071-2360 | NuCare Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (68071-2360-1) | March 11, 2021 |
| 68071-3273-3 | 68071-3273 | NuCare Pharmaceuticals,Inc. | 30 TABLET in 1 BOTTLE (68071-3273-3) | January 29, 2019 |
| 68071-3273-6 | 68071-3273 | NuCare Pharmaceuticals,Inc. | 60 TABLET in 1 BOTTLE (68071-3273-6) | December 19, 2023 |
| 68071-3273-9 | 68071-3273 | NuCare Pharmaceuticals,Inc. | 90 TABLET in 1 BOTTLE (68071-3273-9) | December 19, 2023 |
| 68071-3536-3 | 68071-3536 | NuCare Pharmaceuticals,Inc. | 30 TABLET in 1 BOTTLE (68071-3536-3) | November 28, 2023 |
| 68071-3536-9 | 68071-3536 | NuCare Pharmaceuticals,Inc. | 90 TABLET in 1 BOTTLE (68071-3536-9) | September 14, 2026 |
| 68071-4445-1 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 10 TABLET in 1 BOTTLE (68071-4445-1) | May 21, 2018 |
| 68071-4445-2 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 20 TABLET in 1 BOTTLE (68071-4445-2) | May 21, 2018 |
| 68071-4445-3 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 30 TABLET in 1 BOTTLE (68071-4445-3) | May 21, 2018 |
| 68071-4445-4 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 40 TABLET in 1 BOTTLE (68071-4445-4) | May 21, 2018 |
| 68071-4445-6 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 60 TABLET in 1 BOTTLE (68071-4445-6) | May 21, 2018 |
| 68071-4445-8 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 180 TABLET in 1 BOTTLE (68071-4445-8) | May 21, 2018 |
| 68071-4445-9 | 68071-4445 | NuCare Pharmaceuticals,Inc. | 90 TABLET in 1 BOTTLE (68071-4445-9) | May 21, 2018 |
| 68071-4522-1 | 68071-4522 | NuCare Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE (68071-4522-1) | August 10, 2018 |
| 68071-4534-1 | 68071-4534 | NuCare Pharmaceuticals,Inc. | 100 TABLET in 1 BOTTLE (68071-4534-1) | August 20, 2018 |
| 43063-702-21 | 43063-702 | PD-Rx Pharmaceuticals, Inc. | 21 TABLET in 1 BOTTLE, PLASTIC (43063-702-21) | January 31, 2017 |
| 43063-702-30 | 43063-702 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (43063-702-30) | September 29, 2016 |
| 43063-702-60 | 43063-702 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (43063-702-60) | August 10, 2016 |
| 43063-702-79 | 43063-702 | PD-Rx Pharmaceuticals, Inc. | 1 TABLET in 1 BOTTLE, PLASTIC (43063-702-79) | February 21, 2017 |
| 43063-702-90 | 43063-702 | PD-Rx Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (43063-702-90) | January 4, 2017 |
| 43063-716-01 | 43063-716 | PD-Rx Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (43063-716-01) | May 16, 2017 |
| 43063-716-30 | 43063-716 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (43063-716-30) | October 12, 2016 |
| 43063-716-60 | 43063-716 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (43063-716-60) | October 16, 2016 |
| 43063-716-90 | 43063-716 | PD-Rx Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (43063-716-90) | January 6, 2017 |
| 43063-849-21 | 43063-849 | PD-Rx Pharmaceuticals, Inc. | 21 TABLET in 1 BOTTLE, PLASTIC (43063-849-21) | April 27, 2018 |
| 43063-849-30 | 43063-849 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (43063-849-30) | April 27, 2018 |
| 43063-849-60 | 43063-849 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (43063-849-60) | May 3, 2018 |
| 43063-849-90 | 43063-849 | PD-Rx Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE, PLASTIC (43063-849-90) | May 3, 2018 |
| 72789-030-30 | 72789-030 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (72789-030-30) | December 5, 2019 |
| 72789-030-60 | 72789-030 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (72789-030-60) | December 5, 2019 |
| 72789-032-30 | 72789-032 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (72789-032-30) | December 9, 2019 |
| 72789-032-60 | 72789-032 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (72789-032-60) | December 9, 2019 |
| 72789-033-01 | 72789-033 | PD-Rx Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (72789-033-01) | March 9, 2021 |
| 72789-033-30 | 72789-033 | PD-Rx Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE, PLASTIC (72789-033-30) | December 9, 2019 |
| 72789-033-60 | 72789-033 | PD-Rx Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE, PLASTIC (72789-033-60) | December 9, 2019 |
| 72789-033-82 | 72789-033 | PD-Rx Pharmaceuticals, Inc. | 500 TABLET in 1 BOTTLE, PLASTIC (72789-033-82) | March 9, 2021 |
| 72789-157-01 | 72789-157 | PD-Rx Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE, PLASTIC (72789-157-01) | January 12, 2021 |
| 68788-6948-1 | 68788-6948 | Preferred Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (68788-6948-1) | April 17, 2017 |
| 68788-6948-3 | 68788-6948 | Preferred Pharmaceuticals Inc. | 30 TABLET in 1 BOTTLE (68788-6948-3) | April 17, 2017 |
| 68788-6948-6 | 68788-6948 | Preferred Pharmaceuticals Inc. | 60 TABLET in 1 BOTTLE (68788-6948-6) | April 17, 2017 |
| 68788-6948-9 | 68788-6948 | Preferred Pharmaceuticals Inc. | 90 TABLET in 1 BOTTLE (68788-6948-9) | April 17, 2017 |
| 68788-8799-1 | 68788-8799 | Preferred Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (68788-8799-1) | January 1, 2025 |
| 68788-8799-3 | 68788-8799 | Preferred Pharmaceuticals Inc. | 30 TABLET in 1 BOTTLE (68788-8799-3) | January 1, 2025 |
| 68788-8799-6 | 68788-8799 | Preferred Pharmaceuticals Inc. | 60 TABLET in 1 BOTTLE (68788-8799-6) | January 1, 2025 |
| 68788-8799-9 | 68788-8799 | Preferred Pharmaceuticals Inc. | 90 TABLET in 1 BOTTLE (68788-8799-9) | January 1, 2025 |
| 68788-6784-1 | 68788-6784 | Preferred Pharmaceuticals, Inc. | 100 TABLET in 1 BOTTLE (68788-6784-1) | October 25, 2016 |
| 68788-6784-3 | 68788-6784 | Preferred Pharmaceuticals, Inc. | 30 TABLET in 1 BOTTLE (68788-6784-3) | October 25, 2016 |
| 68788-6784-6 | 68788-6784 | Preferred Pharmaceuticals, Inc. | 60 TABLET in 1 BOTTLE (68788-6784-6) | October 25, 2016 |
| 68788-6784-9 | 68788-6784 | Preferred Pharmaceuticals, Inc. | 90 TABLET in 1 BOTTLE (68788-6784-9) | October 25, 2016 |
| 68788-8870-1 | 68788-8870 | Prefferred Pharmaceuticals Inc. | 100 TABLET in 1 BOTTLE (68788-8870-1) | April 30, 2025 |
| 68788-8870-3 | 68788-8870 | Prefferred Pharmaceuticals Inc. | 30 TABLET in 1 BOTTLE (68788-8870-3) | April 30, 2025 |
| 68788-8870-6 | 68788-8870 | Prefferred Pharmaceuticals Inc. | 60 TABLET in 1 BOTTLE (68788-8870-6) | April 30, 2025 |
| 68788-8870-9 | 68788-8870 | Prefferred Pharmaceuticals Inc. | 90 TABLET in 1 BOTTLE (68788-8870-9) | April 30, 2025 |
| 63187-506-30 | 63187-506 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-506-30) | December 1, 2018 |
| 63187-506-60 | 63187-506 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-506-60) | December 1, 2018 |
| 63187-506-90 | 63187-506 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-506-90) | December 1, 2018 |
| 63187-517-30 | 63187-517 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-517-30) | December 1, 2018 |
| 63187-517-60 | 63187-517 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-517-60) | December 1, 2018 |
| 63187-517-90 | 63187-517 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-517-90) | December 1, 2018 |
| 63187-739-10 | 63187-739 | Proficient Rx LP | 10 TABLET in 1 BOTTLE (63187-739-10) | March 1, 2017 |
| 63187-739-30 | 63187-739 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-739-30) | October 3, 2016 |
| 63187-739-60 | 63187-739 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-739-60) | October 3, 2016 |
| 63187-739-90 | 63187-739 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-739-90) | October 3, 2016 |
| 63187-790-07 | 63187-790 | Proficient Rx LP | 7 TABLET in 1 BOTTLE (63187-790-07) | July 18, 2025 |
| 63187-790-30 | 63187-790 | Proficient Rx LP | 30 TABLET in 1 BOTTLE (63187-790-30) | December 1, 2016 |
| 63187-790-60 | 63187-790 | Proficient Rx LP | 60 TABLET in 1 BOTTLE (63187-790-60) | December 1, 2016 |
| 63187-790-90 | 63187-790 | Proficient Rx LP | 90 TABLET in 1 BOTTLE (63187-790-90) | December 1, 2016 |
| 42708-123-30 | 42708-123 | QPharma Inc | 30 TABLET in 1 BOTTLE (42708-123-30) | May 23, 2018 |
| 70518-0050-0 | 70518-0050 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-0050-0) | December 12, 2016 |
| 70518-0050-1 | 70518-0050 | REMEDYREPACK INC. | 90 TABLET in 1 BOTTLE (70518-0050-1) | December 30, 2016 |
| 70518-0050-2 | 70518-0050 | REMEDYREPACK INC. | 100 TABLET in 1 BOTTLE, PLASTIC (70518-0050-2) | February 1, 2017 |
| 70518-0050-4 | 70518-0050 | REMEDYREPACK INC. | 30 TABLET in 1 BOTTLE, PLASTIC (70518-0050-4) | November 3, 2018 |
| 70518-0251-1 | 70518-0251 | REMEDYREPACK INC. | 90 TABLET in 1 BOTTLE, PLASTIC (70518-0251-1) | March 17, 2017 |
| 70518-0251-3 | 70518-0251 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-0251-3) | April 10, 2018 |
| 70518-2528-1 | 70518-2528 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-2528-1) | August 21, 2025 |
| 70518-3061-2 | 70518-3061 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-3061-2) | November 29, 2023 |
| 70518-3061-6 | 70518-3061 | REMEDYREPACK INC. | 50 POUCH in 1 BOX (70518-3061-6) / 1 TABLET in 1 POUCH (70518-3061-7) | April 23, 2026 |
| 70518-3757-0 | 70518-3757 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-3757-0) | June 11, 2023 |
| 70518-4609-0 | 70518-4609 | REMEDYREPACK INC. | 50 POUCH in 1 BOX (70518-4609-0) / 1 TABLET in 1 POUCH (70518-4609-1) | April 23, 2026 |
| 70518-4679-0 | 70518-4679 | REMEDYREPACK INC. | 30 TABLET in 1 BLISTER PACK (70518-4679-0) | June 22, 2026 |
| 67296-2136-1 | 67296-2136 | Redpharm Drug | 3 TABLET in 1 BOTTLE (67296-2136-1) | November 5, 2022 |
| 67296-2136-2 | 67296-2136 | Redpharm Drug | 6 TABLET in 1 BOTTLE (67296-2136-2) | November 5, 2022 |
| 67296-2136-3 | 67296-2136 | Redpharm Drug | 30 TABLET in 1 BOTTLE (67296-2136-3) | November 5, 2022 |
| 67296-2136-4 | 67296-2136 | Redpharm Drug | 7 TABLET in 1 BOTTLE (67296-2136-4) | November 5, 2022 |
| 67296-2136-5 | 67296-2136 | Redpharm Drug | 5 TABLET in 1 BOTTLE (67296-2136-5) | November 5, 2022 |
| 67296-2136-6 | 67296-2136 | Redpharm Drug | 10 TABLET in 1 BOTTLE (67296-2136-6) | November 5, 2022 |
| 67296-2139-3 | 67296-2139 | Redpharm Drug | 30 TABLET in 1 BOTTLE (67296-2139-3) | November 5, 2022 |
| 64980-562-01 | 64980-562 | Rising Pharma Holdings, Inc. | 100 TABLET in 1 BOTTLE (64980-562-01) | November 5, 2022 |
| 64980-562-10 | 64980-562 | Rising Pharma Holdings, Inc. | 1000 TABLET in 1 BOTTLE (64980-562-10) | November 5, 2022 |
| 64980-563-01 | 64980-563 | Rising Pharma Holdings, Inc. | 100 TABLET in 1 BOTTLE (64980-563-01) | November 5, 2022 |
| 64980-563-10 | 64980-563 | Rising Pharma Holdings, Inc. | 1000 TABLET in 1 BOTTLE (64980-563-10) | November 5, 2022 |
| 64980-564-01 | 64980-564 | Rising Pharma Holdings, Inc. | 100 TABLET in 1 BOTTLE (64980-564-01) | November 5, 2022 |
| 64980-564-50 | 64980-564 | Rising Pharma Holdings, Inc. | 500 TABLET in 1 BOTTLE (64980-564-50) | November 5, 2022 |
| 43547-401-10 | 43547-401 | Solco Healthcare LLC | 100 TABLET in 1 BOTTLE, PLASTIC (43547-401-10) | March 26, 2004 |
| 43547-401-11 | 43547-401 | Solco Healthcare LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (43547-401-11) | March 26, 2004 |
| 43547-401-51 | 43547-401 | Solco Healthcare LLC | 5000 TABLET in 1 BOTTLE, PLASTIC (43547-401-51) | March 26, 2004 |
| 43547-401-94 | 43547-401 | Solco Healthcare LLC | 2000000 TABLET in 1 DRUM (43547-401-94) | January 1, 2022 |
| 43547-402-10 | 43547-402 | Solco Healthcare LLC | 100 TABLET in 1 BOTTLE, PLASTIC (43547-402-10) | March 26, 2004 |
| 43547-402-11 | 43547-402 | Solco Healthcare LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (43547-402-11) | March 26, 2004 |
| 43547-402-51 | 43547-402 | Solco Healthcare LLC | 5000 TABLET in 1 BOTTLE, PLASTIC (43547-402-51) | March 26, 2004 |
| 43547-402-94 | 43547-402 | Solco Healthcare LLC | 1000000 TABLET in 1 DRUM (43547-402-94) | January 1, 2022 |
| 43547-403-10 | 43547-403 | Solco Healthcare LLC | 100 TABLET in 1 BOTTLE, PLASTIC (43547-403-10) | March 26, 2004 |
| 43547-403-11 | 43547-403 | Solco Healthcare LLC | 1000 TABLET in 1 BOTTLE, PLASTIC (43547-403-11) | March 26, 2004 |
| 43547-403-50 | 43547-403 | Solco Healthcare LLC | 500 TABLET in 1 BOTTLE, PLASTIC (43547-403-50) | March 26, 2004 |
| 43547-403-94 | 43547-403 | Solco Healthcare LLC | 500000 TABLET in 1 DRUM (43547-403-94) | January 1, 2022 |
| 60760-858-90 | 60760-858 | St. Mary's Medical Park Pharmacy | 90 TABLET in 1 BOTTLE, PLASTIC (60760-858-90) | June 15, 2023 |
| 87441-033-01 | 87441-033 | Unit Dose Solutions, Inc. | 30 TABLET in 1 BLISTER PACK (87441-033-01) | June 22, 2026 |
| 50090-2713 | 50090-2713 | A-S Medication Solutions | — | February 1, 2006 |
| 50090-3313 | 50090-3313 | A-S Medication Solutions | — | February 1, 2006 |
| 50090-5429 | 50090-5429 | A-S Medication Solutions | — | February 1, 2006 |
| 50090-5702 | 50090-5702 | A-S Medication Solutions | — | February 1, 2006 |
| 50090-6219 | 50090-6219 | A-S Medication Solutions | — | November 10, 1983 |
| 50090-6642 | 50090-6642 | A-S Medication Solutions | — | November 5, 2022 |
| 50090-6646 | 50090-6646 | A-S Medication Solutions | — | November 5, 2022 |
| 50090-6647 | 50090-6647 | A-S Medication Solutions | — | November 5, 2022 |
| 50090-6937 | 50090-6937 | A-S Medication Solutions | — | February 1, 2006 |
| 50090-6942 | 50090-6942 | A-S Medication Solutions | — | November 5, 2022 |
| 50090-7703 | 50090-7703 | A-S Medication Solutions | — | June 3, 2024 |
| 50090-7704 | 50090-7704 | A-S Medication Solutions | — | June 3, 2024 |
| 50090-7705 | 50090-7705 | A-S Medication Solutions | — | June 3, 2024 |
| 50090-7706 | 50090-7706 | A-S Medication Solutions | — | June 3, 2024 |
| 50090-7708 | 50090-7708 | A-S Medication Solutions | — | June 3, 2024 |
| 43353-069 | 43353-069 | Aphena Pharma Solutions - Tennessee, LLC | — | November 10, 1983 |
| 43353-747 | 43353-747 | Aphena Pharma Solutions - Tennessee, LLC | — | November 10, 1983 |
| 71610-049 | 71610-049 | Aphena Pharma Solutions - Tennessee, LLC | — | March 26, 2004 |
| 71610-096 | 71610-096 | Aphena Pharma Solutions - Tennessee, LLC | — | March 26, 2004 |
| 71610-634 | 71610-634 | Aphena Pharma Solutions - Tennessee, LLC | — | January 4, 2022 |
| 71610-635 | 71610-635 | Aphena Pharma Solutions - Tennessee, LLC | — | January 4, 2022 |
| 71610-636 | 71610-636 | Aphena Pharma Solutions - Tennessee, LLC | — | January 4, 2022 |
| 71610-843 | 71610-843 | Aphena Pharma Solutions - Tennessee, LLC | — | February 1, 2006 |
| 71610-951 | 71610-951 | Aphena Pharma Solutions - Tennessee, LLC | — | February 1, 2006 |
| 59651-796 | 59651-796 | Aurobindo Pharma Limited | — | July 17, 2025 |
| 59651-797 | 59651-797 | Aurobindo Pharma Limited | — | July 17, 2025 |
| 59651-798 | 59651-798 | Aurobindo Pharma Limited | — | July 17, 2025 |
| 42291-468 | 42291-468 | AvKARE | — | January 4, 2022 |
| 42291-469 | 42291-469 | AvKARE | — | January 4, 2022 |
| 42291-470 | 42291-470 | AvKARE | — | January 4, 2022 |
| 63629-1119 | 63629-1119 | Bryant Ranch Prepack | — | July 30, 2020 |
| 63629-1120 | 63629-1120 | Bryant Ranch Prepack | — | July 30, 2020 |
| 63629-1214 | 63629-1214 | Bryant Ranch Prepack | — | March 26, 2004 |
| 63629-1215 | 63629-1215 | Bryant Ranch Prepack | — | March 26, 2004 |
| 63629-1216 | 63629-1216 | Bryant Ranch Prepack | — | March 26, 2004 |
| 63629-1217 | 63629-1217 | Bryant Ranch Prepack | — | March 26, 2004 |
| 71335-0384 | 71335-0384 | Bryant Ranch Prepack | — | February 1, 2006 |
| 71335-0842 | 71335-0842 | Bryant Ranch Prepack | — | March 26, 2004 |
| 71335-0852 | 71335-0852 | Bryant Ranch Prepack | — | March 26, 2004 |
| 71335-2317 | 71335-2317 | Bryant Ranch Prepack | — | November 5, 2022 |
| 71335-2319 | 71335-2319 | Bryant Ranch Prepack | — | November 5, 2022 |
| 72162-1360 | 72162-1360 | Bryant Ranch Prepack | — | March 26, 2004 |
| 72162-1361 | 72162-1361 | Bryant Ranch Prepack | — | March 26, 2004 |
| 72162-1362 | 72162-1362 | Bryant Ranch Prepack | — | March 26, 2004 |
| 17224-178 | 17224-178 | Calvin Scott & Co., Inc. | — | February 1, 2006 |
| 17224-185 | 17224-185 | Calvin Scott & Co., Inc. | — | February 1, 2006 |
| 55154-2348 | 55154-2348 | Cardinal Health 107, LLC | — | December 4, 2024 |
| 55154-2349 | 55154-2349 | Cardinal Health 107, LLC | — | December 4, 2024 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.